Guy G Brusselle

List of Publications by Year
in descending order

305	22,911	9428 76	12272 138
papers	citations	h-index	g-index

309	309	309	25427
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Novel genetic variants associated with inhaled corticosteroid treatment response in older adults with asthma. Thorax, 2023, 78, 432-441.	2.7	5
2	Antiâ€“Interleukin-5 Therapy Is Associated with Attenuated Lung Function Decline in Severe Eosinophilic Asthma Patients From the Belgian Severe Asthma Registry. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 467-477.	2.0	13
3	Pharmacogenetics of inhaled corticosteroids and exacerbation risk in adults with asthma. Clinical and Experimental Allergy, 2022, 52, 33-45.	1.4	11
4	ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations. European Respiratory Journal, 2022, 59, 2102006.	3.1	34
5	Global Initiative for Asthma Strategy 2021. Respirology, 2022, 27, 14-35.	1.3	31
6	Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes. European Respiratory Journal, 2022, 59, 2102730.	3.1	218
7	Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 17-35.	2.5	196
8	Changes in lung function in European adults born between 1884 and 1996 and implications for the diagnosis of lung disease: a cross-sectional analysis of ten population-based studies. Lancet Respiratory Medicine,the, 2022, 10, 83-94.	5.2	19
9	Global Initiative for Asthma Strategy 2021. Executive Summary and Rationale for Key Changes. Archivos De Bronconeumologia, 2022, 58, 35-51.	0.4	31
10	Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, S1-S18.	2.0	66
11	Biologic Therapies for Severe Asthma. New England Journal of Medicine, 2022, 386, 157-171.	13.9	268
12	Non-typeable Haemophilus influenzaeâ€“Moraxella catarrhalis vaccine for the prevention of exacerbations in chronic obstructive pulmonary disease: a multicentre, randomised, placebo-controlled, observer-blinded, proof-of-concept, phase 2b trial. Lancet Respiratory Medicine,the, 2022, 10, 435-446.	5.2	16
13	Genetic Associations and Architecture of Asthma-COPD Overlap. Chest, 2022, 161, 1155-1166.	0.4	15
14	Real-life effectiveness of mepolizumab in severe asthma: a systematic literature review. Journal of Asthma, 2022, 59, 2201-2217.	0.9	18
15	Lung function impairment in relation to cognition and vascular brain lesions: the Rotterdam Study. Journal of Neurology, 2022, 269, 4141-4153.	1.8	4
16	The interrelationship of chronic cough and depression: a prospective population-based study. ERJ Open Research, 2022, 8, 00069-2022.	1.1	12
17	Characterization of Asthma by Age of Onset: A Multi-Database Cohort Study. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 1825-1834.e8.	2.0	19
18	Sarcopenia, systemic immune-inflammation index and all-cause mortality in middle-aged and older people with COPD and asthma: a population-based study. ERJ Open Research, 2022, 8, 00628-2021.	1.1	9

#	Article	IF	Citations
19	Disease-modifying anti-asthmatic drugs. Lancet, The, 2022, 399, 1664-1668.	6.3	42
20	Pulmonary Function and Blood DNA Methylation: A Multiancestry Epigenome-Wide Association Meta-analysis. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 321-336.	2.5	15
21	Serum Immunoglobulins, Pneumonia Risk, and Lung Function in Middle-Aged and Older Individuals: A Population-Based Cohort Study. Frontiers in Immunology, 2022, 13, .	2.2	4
22	Multiâ€ancestry genomeâ€wide association study of asthma exacerbations. Pediatric Allergy and Immunology, 2022, 33, .	1.1	14
23	The low flyers: persistent airflow limitation in young adults. Lancet Respiratory Medicine,the, 2022, 10, 819-822.	5.2	2
24	ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 168-190.	2.7	46
25	Treatment options in type-2 low asthma. European Respiratory Journal, 2021, 57, 2000528.	3.1	80
26	Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. Lancet Respiratory Medicine,the, 2021, 9, 69-84.	5.2	135
27	The interrelatedness of chronic cough and chronic pain. European Respiratory Journal, 2021, 57, 2002651.	3.1	19
28	Quantification and role of innate lymphoid cell subsets in Chronic Obstructive Pulmonary Disease. Clinical and Translational Immunology, 2021, 10, e1287.	1.7	15
29	Effect of ACE1 polymorphism rs1799752 on protein levels of ACE2, the SARS-CoV-2 entry receptor, in alveolar lung epithelium. ERJ Open Research, 2021, 7, 00940-2020.	1.1	18
30	Effect of Î²-blockers on the risk of COPD exacerbations according to indication of use: the Rotterdam Study. ERJ Open Research, 2021, 7, 00624-2020.	1.1	2
31	Cluster Analysis of Inflammatory Biomarker Expression in the International Severe Asthma Registry. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2680-2688.e7.	2.0	50
32	Beclometasone dipropionate/formoterol maintenance and reliever therapy asthma exacerbation benefit increases with blood eosinophil level. European Respiratory Journal, 2021, 58, 2004098.	3.1	5
33	Incidence and predictors of asthma exacerbations in middle-aged and older adults: the Rotterdam Study. ERJ Open Research, 2021, 7, 00126-2021.	1.1	1
34	Patient characteristics, biomarkers and exacerbation risk in severe, uncontrolled asthma. European Respiratory Journal, 2021, 58, 2100413.	3.1	43
35	Lung Function Impairment and the Risk of Incident Dementia: The Rotterdam Study. Journal of Alzheimer's Disease, 2021, 82, 621-630.	1.2	10
36	A systematic analysis of protein-altering exonic variants in chronic obstructive pulmonary disease. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2021, 321, L130-L143.	1.3	11

#	Article	IF	Citations
37	Eosinophilic and Noneosinophilic Asthma. Chest, 2021, 160, 814-830.	0.4	109
38	Necroptosis Signaling Promotes Inflammation, Airway Remodeling, and Emphysema in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 667-681.	2.5	85
39	Rare and low-frequency exonic variants and gene-by-smoking interactions in pulmonary function. Scientific Reports, 2021, 11, 19365.	1.6	2
40	Incidence, prevalence and long-term progression of Goh algorithm rated interstitial lung disease in systemic sclerosis in two independent cohorts in flanders: A retrospective cohort study. Seminars in Arthritis and Rheumatism, 2021, 51, 969-976.	1.6	8
41	Mepolizumab for chronic rhinosinusitis with nasal polyps. Lancet Respiratory Medicine,the, 2021, 9, 1081-1082.	5.2	6
42	Epigenome-wide association study on diffusing capacity of the lung. ERJ Open Research, 2021, 7, 00567-2020.	1.1	3
43	MiR-223 is increased in lungs of patients with COPD and modulates cigarette smoke-induced pulmonary inflammation. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2021, 321, L1091-L1104.	1.3	9
44	3TR: a pan-European cross-disease research consortium aimed at improving personalised biological treatment of asthma and COPD. European Respiratory Journal, 2021, 58, 2102168.	3.1	8
45	Sarcopenia in older people with chronic airway diseases: the Rotterdam study. ERJ Open Research, 2021, 7, 00522-2020.	1.1	8
46	A microRNA-21â€“mediated SATB1/S100A9/NF-ÎºB axis promotes chronic obstructive pulmonary disease pathogenesis. Science Translational Medicine, 2021, 13, eaav7223.	5.8	54
47	Comparison of cerebral blood flow in subjects with and without chronic obstructive pulmonary disease from the population-based Rotterdam Study. BMJ Open, 2021, 11, e053671.	0.8	2
48	Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. Journal of Allergy and Clinical Immunology, 2020, 145, 70-80.e3.	1.5	272
49	Trajectory and mortality of preserved ratio impaired spirometry: the Rotterdam Study. European Respiratory Journal, 2020, 55, 1901217.	3.1	107
50	The impact of the prostaglandin D₂ receptor 2 and its downstream effects on the pathophysiology of asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 761-768.	2.7	40
51	Recent advances in chronic obstructive pulmonary disease pathogenesis: from disease mechanisms to precision medicine. Journal of Pathology, 2020, 250, 624-635.	2.1	116
52	Simultaneous inhibition of thymic stromal lymphopoietin, ILâ€33 and ILâ€25: A therapeutic option in asthma?. Respirology, 2020, 25, 566-567.	1.3	0
53	Safety of Reslizumab in Uncontrolled Asthma with Eosinophilia: A Pooled Analysis from 6 Trials. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 540-548.e1.	2.0	23
54	Expression of ACE2, the SARS-CoV-2 Receptor, in Lung Tissue of Patients With Type 2 Diabetes. Diabetes, 2020, 69, 2691-2699.	0.3	55

#	Article	IF	Citations
55	A new once-daily long-acting Î²2-adrenoceptor agonistâ€“inhaled corticosteroid combination therapy for asthma. Lancet Respiratory Medicine,the, 2020, 8, 936-937.	5.2	0
56	Blood eosinophil level and lung function trajectories: cross-sectional and longitudinal studies in European cohorts. ERJ Open Research, 2020, 6, 00320-2020.	1.1	9
57	Reply to Lipworth et al.: Inhaled Corticosteroids and COVID-19. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 900-902.	2.5	10
58	A cross-omics integrative study of metabolic signatures of chronic obstructive pulmonary disease. BMC Pulmonary Medicine, 2020, 20, 193.	0.8	15
59	Increased expression of ACE2, the SARS-CoV-2 entry receptor, in alveolar and bronchial epithelium of smokers and COPD subjects. European Respiratory Journal, 2020, 56, 2002378.	3.1	67
60	Chronic obstructive pulmonary disease and related phenotypes: polygenic risk scores in population-based and case-control cohorts. Lancet Respiratory Medicine,the, 2020, 8, 696-708.	5.2	69
61	Translational research into the effects of cigarette smoke on inflammatory mediators and epithelial TRPV1 in Crohnâ€™s disease. PLoS ONE, 2020, 15, e0236657.	1.1	3
62	COVID-19 and biologics in severe asthma: data from the Belgian Severe Asthma Registry. European Respiratory Journal, 2020, 56, 2002857.	3.1	52
63	International severe asthma registry (ISAR): protocol for a global registry. BMC Medical Research Methodology, 2020, 20, 212.	1.4	29
64	The global significance of PRISm: how data from low- and middle-income countries link physiology to inflammation. European Respiratory Journal, 2020, 55, 2000354.	3.1	3
65	Objectives, design and main findings until 2020 from the Rotterdam Study. European Journal of Epidemiology, 2020, 35, 483-517.	2.5	314
66	Innate lymphoid cells in isocyanate-induced asthma: role of microRNA-155. European Respiratory Journal, 2020, 56, 1901289.	3.1	6
67	Expanding the spectrum of European Respiratory Society official scientific documents: short documents complement clinical practice guidelines, statements and technical standards. European Respiratory Journal, 2020, 55, 2001030.	3.1	3
68	GINA fosters World Asthma Day 2020 to prevent asthma deaths. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2020, 318, L998-L1000.	1.3	8
69	Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respiratory Medicine,the, 2020, 8, 461-474.	5.2	56
70	Severe eosinophilic asthma with nasal polyposis: A phenotype for improved sinonasal and asthma outcomes with mepolizumab therapy. Journal of Allergy and Clinical Immunology, 2020, 145, 1713-1715.	1.5	42
71	Change in blood eosinophils following treatment with inhaled corticosteroids may predict long-term clinical response in COPD. European Respiratory Journal, 2020, 55, 1902119.	3.1	26
72	Prevalence and incidence of, and risk factors for chronic cough in the adult population: the Rotterdam Study. ERJ Open Research, 2020, 6, 00300-2019.	1.1	44

#	Article	IF	Citations
73	Charting Extracellular Transcriptomes in The Human Biofluid RNA Atlas. Cell Reports, 2020, 33, 108552.	2.9	50
74	COVID-19, Asthma, and Inhaled Corticosteroids: Another Beneficial Effect of Inhaled Corticosteroids?. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 8-10.	2.5	38
75	FENO as a biomarker guide for inhaled corticosteroid step down in patients with mild-to-moderate well-controlled asthma. European Respiratory Journal, 2020, 55, 2001319.	3.1	9
76	Core outcome set for the management of acute exacerbations of chronic obstructive pulmonary disease: the COS-AECOPD ERS Task Force study protocol. ERJ Open Research, 2020, 6, 00193-2020.	1.1	14
77	Title is missing!. , 2020, 15, e0236657.		0
78	Title is missing!. , 2020, 15, e0236657.		0
79	Title is missing!. , 2020, 15, e0236657.		0
80	Title is missing!. , 2020, 15, e0236657.		0
81	Title is missing!. , 2020, 15, e0236657.		0
82	Prevalence of Asthma and COPD and Blood Eosinophil Count in a Middle-Aged Belgian Population. Journal of Clinical Medicine, 2019, 8, 1122.	1.0	9
83	GINA 2019: a fundamental change in asthma management. European Respiratory Journal, 2019, 53, 1901046.	3.1	277
84	Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. Lancet Respiratory Medicine,the, 2019, 7, 745-756.	5.2	159
85	Treatment failure and hospital readmissions in severe COPD exacerbations treated with azithromycin versus placebo â€“ a post-hoc analysis of the BACE randomized controlled trial. Respiratory Research, 2019, 20, 237.	1.4	16
86	Inhaled corticosteroids in COPD and onset of type 2 diabetes and osteoporosis: matched cohort study. Npj Primary Care Respiratory Medicine, 2019, 29, 38.	1.1	27
87	Î²2-Adrenergic Receptor (ADRB2) Gene Polymorphisms and Risk of COPD Exacerbations: The Rotterdam Study. Journal of Clinical Medicine, 2019, 8, 1835.	1.0	12
88	Atherosclerotic calcification in major vessel beds in chronic obstructive pulmonary disease: The Rotterdam Study. Atherosclerosis, 2019, 291, 107-113.	0.4	9
89	Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study. Clinical Therapeutics, 2019, 41, 2041-2056.e5.	1.1	102
90	ERS/EAACI statement on severe exacerbations in asthma in adults: facts, priorities and key research questions. European Respiratory Journal, 2019, 54, 1900900.	3.1	56

#	Article	IF	Citations
91	Next-generation care pathways for allergic rhinitis and asthma multimorbidity: a model for multimorbid non-communicable diseasesâ€"Meeting Report (Part 1). Journal of Thoracic Disease, 2019, 11, 3633-3642.	0.6	11
92	Does maintenance azithromycin reduce asthma exacerbations? An individual participant data meta-analysis. European Respiratory Journal, 2019, 54, 1901381.	3.1	47
93	Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases. Clinical and Translational Allergy, 2019, 9, 44.	1.4	87
94	Next-generation care pathways for allergic rhinitis and asthma multimorbidity: a model for multimorbid non-communicable diseasesâ€"Meeting Report (Part 2). Journal of Thoracic Disease, 2019, 11, 4072-4084.	0.6	15
95	Prevalence and burden of asthma in China: time to act. Lancet, The, 2019, 394, 364-366.	6.3	23
96	Prevalence and Characteristics of Asthmaâ€"Chronic Obstructive Pulmonary Disease Overlap in Routine Primary Care Practices. Annals of the American Thoracic Society, 2019, 16, 1143-1150.	1.5	32
97	Update on immunogenicity in severe asthma: Experience with mepolizumab. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 2469-2475.e1.	2.0	4
98	The once-daily fixed-dose combination of olodaterol and tiotropium in the management of COPD: current evidence and future prospects. Therapeutic Advances in Respiratory Disease, 2019, 13, 175346661984342.	1.0	3
99	Azithromycin during Acute Chronic Obstructive Pulmonary Disease Exacerbations Requiring Hospitalization (BACE). A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 857-868.	2.5	48
100	Chronic Airway Diseases Early Stratification (CADSET): a new ERS Clinical Research Collaboration. European Respiratory Journal, 2019, 53, 1900217.	3.1	25
101	Limited overlap in significant hits between genome-wide association studies on two airflow obstruction definitions in the same population. BMC Pulmonary Medicine, 2019, 19, 58.	0.8	4
102	Quality standards in respiratory real-life effectiveness research: the REal Life EVidence AssessmeNt Tool (RELEVANT): report from the Respiratory Effectiveness Groupâ€"European Academy of Allergy and Clinical Immunology Task Force. Clinical and Translational Allergy, 2019, 9, 20.	1.4	20
103	The REal Life EVidence AssessmeNt Tool (RELEVANT): development of a novel quality assurance asset to rate observational comparative effectiveness research studies. Clinical and Translational Allergy, 2019, 9, 21.	1.4	24
104	Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma. Respiratory Medicine, 2019, 150, 51-62.	1.3	31
105	Newborn DNA-methylation, childhood lung function, and the risks of asthma and COPD across the life course. European Respiratory Journal, 2019, 53, 1801795.	3.1	48
106	Genetic landscape of chronic obstructive pulmonary disease identifies heterogeneous cell-type and phenotype associations. Nature Genetics, 2019, 51, 494-505.	9.4	257
107	The ERS fellowship portfolio: fostering excellence and diversity. European Respiratory Journal, 2019, 54, 1901503.	3.1	3
108	Sarcopenia in COPD: a systematic review and meta-analysis. European Respiratory Review, 2019, 28, 190049.	3.0	116

#	Article	IF	Citations
109	DNA methylation is associated with lung function in never smokers. Respiratory Research, 2019, 20, 268.	1.4	14
110	Association of alcohol consumption with allergic disease and asthma: a multiâ€centre Mendelian randomization analysis. Addiction, 2019, 114, 216-225.	1.7	14
111	Omega-3 Fatty Acids and Genome-Wide Interaction Analyses Reveal DPP10â€“Pulmonary Function Association. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 631-642.	2.5	14
112	Tralokinumab did not demonstrate oral corticosteroid-sparing effects in severe asthma. European Respiratory Journal, 2019, 53, 1800948.	3.1	49
113	The association between dietary protein intake, energy intake and physical frailty: results from the Rotterdam Study. British Journal of Nutrition, 2019, 121, 393-401.	1.2	36
114	GDF-15 in Pulmonary and Critical Care Medicine. American Journal of Respiratory Cell and Molecular Biology, 2019, 60, 621-628.	1.4	25
115	Chronic obstructive pulmonary disease and the development of atrial fibrillation. International Journal of Cardiology, 2019, 276, 118-124.	0.8	43
116	Association of innate defense proteins BPIFA1 and BPIFB1 with disease severity in COPD. International Journal of COPD, 2018, Volume 13, 11-27.	0.9	27
117	Sarcopenia and Its Clinical Correlates in the General Population: The Rotterdam Study. Journal of Bone and Mineral Research, 2018, 33, 1209-1218.	3.1	51
118	DPP4, the Middle East Respiratory Syndrome Coronavirus Receptor, is Upregulated in Lungs of Smokers and Chronic Obstructive Pulmonary Disease Patients. Clinical Infectious Diseases, 2018, 66, 45-53.	2.9	89
119	COPD GWAS variant at 19q13.2 in relation with DNA methylation and gene expression. Human Molecular Genetics, 2018, 27, 396-405.	1.4	24
120	Understanding the role of the chromosome 15q25.1 in COPD through epigenetics and transcriptomics. European Journal of Human Genetics, 2018, 26, 709-722.	1.4	21
121	Anti-MDA5 positive dermatomyositis complicated with rapidly progressive interstitial lung disease â€“ a case report. Acta Clinica Belgica, 2018, 73, 413-417.	0.5	2
122	Multiancestry association study identifies new asthma risk loci that colocalize with immune-cell enhancer marks. Nature Genetics, 2018, 50, 42-53.	9.4	426
123	Blood eosinophil levels as a biomarker in COPD. Respiratory Medicine, 2018, 138, 21-31.	1.3	86
124	New era for European Respiratory Society clinical practice guidelines: joining efficiency and high methodological standards. European Respiratory Journal, 2018, 51, 1800221.	3.1	23
125	Personalized medicine with biologics for severe type 2 asthma: current status and future prospects. MAbs, 2018, 10, 34-45.	2.6	63
126	After asthma: redefining airways diseases. Lancet, The, 2018, 391, 350-400.	6.3	744

#	Article	IF	Citations
127	Two years follow-up of an open-label pilot study of treatment with rituximab in patients with early diffuse cutaneous systemic sclerosis. Acta Clinica Belgica, 2018, 73, 119-125.	0.5	37
128	COPD is associated with an increased risk of peripheral artery disease and mortality. ERJ Open Research, 2018, 4, 00086-2018.	1.1	16
129	The European Respiratory Society's 10 Principles for Lung Health. European Respiratory Journal, 2018, 52, 1801373.	3.1	6
130	Toward effective prescription of inhaled corticosteroids in chronic airway disease. International Journal of COPD, 2018, Volume 13, 3419-3424.	0.9	2
131	ERS Clinical Research Collaborations: underpinning research excellence. European Respiratory Journal, 2018, 52, 1801534.	3.1	39
132	The European Respiratory Society: ensuring excellence through education best practice. European Respiratory Journal, 2018, 52, 1801248.	3.1	2
133	Meta-analysis across Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium provides evidence for an association of serum vitamin D with pulmonary function. British Journal of Nutrition, 2018, 120, 1159-1170.	1.2	9
134	Performance of database-derived severe exacerbations and asthma control measures in asthma: responsiveness and predictive utility in a UK primary care database with linked questionnaire data. Journal of Pragmatic and Observational Research, 2018, Volume 9, 29-42.	1.1	18
135	<scp>IL</scp>â€33 signalling contributes to pollutantâ€induced allergic airway inflammation. Clinical and Experimental Allergy, 2018, 48, 1665-1675.	1.4	35
136	Serum phosphate levels are related to all-cause, cardiovascular and COPD mortality in men. European Journal of Epidemiology, 2018, 33, 859-871.	2.5	39
137	Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma. New England Journal of Medicine, 2018, 378, 2475-2485.	13.9	816
138	Urgent need for pragmatic trial platforms in severe asthma. Lancet Respiratory Medicine,the, 2018, 6, 581-583.	5.2	15
139	Heritability and genome-wide association study of diffusing capacity of the lung. European Respiratory Journal, 2018, 52, 1800647.	3.1	18
140	Association between blood eosinophil count and risk of readmission for patients with asthma: Historical cohort study. PLoS ONE, 2018, 13, e0201143.	1.1	28
141	A Genome-Wide Linkage Study for Chronic Obstructive Pulmonary Disease in a Dutch Genetic Isolate Identifies Novel Rare Candidate Variants. Frontiers in Genetics, 2018, 9, 133.	1.1	8
142	Multiethnic meta-analysis identifies ancestry-specific and cross-ancestry loci for pulmonary function. Nature Communications, 2018, 9, 2976.	5.8	85
143	Influence of genetic variants on childhood lung function â€“ The Generation R Study. Pediatric Allergy and Immunology, 2018, 29, 589-595.	1.1	10
144	Meta-analysis of exome array data identifies six novel genetic loci for lung function. Wellcome Open Research, 2018, 3, 4.	0.9	19

#	Article	IF	Citations
145	A prospective, longitudinal study evaluating the baseline six-minute walk test as an individual reference value in systemic sclerosis patients. Clinical and Experimental Rheumatology, 2018, 36 Suppl 113, 95-101.	0.4	2
146	Dysregulation of type 2 innate lymphoid cells and T H 2 cells impairs pollutant-induced allergic airway responses. Journal of Allergy and Clinical Immunology, 2017, 139, 246-257.e4.	1.5	55
147	Dietary mineral intake and lung cancer risk: the Rotterdam Study. European Journal of Nutrition, 2017, 56, 1637-1646.	1.8	46
148	Evidence for large-scale gene-by-smoking interaction effects on pulmonary function. International Journal of Epidemiology, 2017, 46, dyw318.	0.9	36
149	Development of a Healthy Aging Score in the Population-Based Rotterdam Study: Evaluating Age and Sex Differences. Journal of the American Medical Directors Association, 2017, 18, 276.e1-276.e7.	1.2	28
150	Peripheral Artery Disease in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 148-150.	2.5	13
151	Reduced Frizzled Receptor 4 Expression Prevents WNT/Î²-Cateninâ€“driven Alveolar Lung Repair in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 172-185.	2.5	85
152	Qualitative evaluation of the St George's Respiratory Questionnaire in patients with severe asthma. Respiratory Medicine, 2017, 126, 32-38.	1.3	19
153	Genetic loci associated with chronic obstructive pulmonary disease overlap with loci for lung function and pulmonary fibrosis. Nature Genetics, 2017, 49, 426-432.	9.4	306
154	Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils. Pulmonary Pharmacology and Therapeutics, 2017, 43, 39-45.	1.1	101
155	Sex-Specific Genetic Risk Factors for Chronic Obstructive Pulmonary Disease. American Journal of Respiratory Cell and Molecular Biology, 2017, 56, 281-282.	1.4	3
156	Reply: Direct Detection of Circulating MicroRNAs Unveiled the Absence of MicroRNA-218-5p in Smoker Subjects. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 533-533.	2.5	0
157	Reslizumab in Eosinophilic Asthma: A Review. Drugs, 2017, 77, 777-784.	4.9	33
158	Screening for pulmonary arterial hypertension in an unselected prospective systemic sclerosis cohort. European Respiratory Journal, 2017, 49, 1602275.	3.1	50
159	Evaluation of the psychometric properties of the St George's Respiratory Questionnaire in patients with severe asthma. Respiratory Medicine, 2017, 128, 42-49.	1.3	7
160	Influence of chronic azithromycin treatment on the composition of the oropharyngeal microbial community in patients with severe asthma. BMC Microbiology, 2017, 17, 109.	1.3	26
161	Pulmonary artery to aorta ratio and risk of all-cause mortality in the general population: the Rotterdam Study. European Respiratory Journal, 2017, 49, 1602168.	3.1	29
162	End-stage cystic fibrosis lung disease is characterised by a diverse inflammatory pattern: an immunohistochemical analysis. Respiratory Research, 2017, 18, 10.	1.4	18

#	Article	IF	Citations
163	Immunological diversity in phenotypes of chronic lung allograft dysfunction: a comprehensive immunohistochemical analysis. Transplant International, 2017, 30, 134-143.	0.8	47
164	Noncanonical WNT-5A signaling impairs endogenous lung repair in COPD. Journal of Experimental Medicine, 2017, 214, 143-163.	4.2	122
165	Pulmonary function and diffusion capacity are associated with pulmonary arterial systolic pressure in the general population: The Rotterdam Study. Respiratory Medicine, 2017, 132, 50-55.	1.3	6
166	microRNA profiling in lung tissue and bronchoalveolar lavage of cigarette smoke-exposed mice and in COPD patients: a translational approach. Scientific Reports, 2017, 7, 12871.	1.6	44
167	Adherence to the 2015 Dutch dietary guidelines and risk of non-communicable diseases and mortality in the Rotterdam Study. European Journal of Epidemiology, 2017, 32, 993-1005.	2.5	111
168	Stratification of eosinophilic asthma patients treated with reslizumab and GINA Step 4 or 5 therapy. ERJ Open Research, 2017, 3, 00004-2017.	1.1	17
169	Taken to task: what is and is not an appropriate response to an ERS guidelines task force?. European Respiratory Journal, 2017, 50, 1700952.	3.1	1
170	Blood eosinophil count and exacerbation risk in patients with COPD. European Respiratory Journal, 2017, 50, 1700761.	3.1	64
171	Epidemiology and impact of chronic bronchitis in chronic obstructive pulmonary disease. European Respiratory Journal, 2017, 50, 1602470.	3.1	70
172	Care pathways for the selection of a biologic in severe asthma. European Respiratory Journal, 2017, 50, 1701782.	3.1	79
173	Azithromycin in uncontrolled asthma. Lancet, The, 2017, 390, 629-630.	6.3	5
174	Genome-wide association study on the FEV 1 /FVC ratio in never-smokers identifies HHIP and FAM13A. Journal of Allergy and Clinical Immunology, 2017, 139, 533-540.	1.5	45
175	MicroRNA Profiling Reveals a Role for MicroRNA-218-5p in the Pathogenesis of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 43-56.	2.5	108
176	Prevalence and incidence of pulmonary arterial hypertension: 10-year follow-up of an unselected systemic sclerosis cohort. Journal of Scleroderma and Related Disorders, 2017, 2, 196-202.	1.0	9
177	Six-minute walk test in or out in evaluation of systemic sclerosis patients?. Clinical and Experimental Rheumatology, 2017, 35 Suppl 106, 122-129.	0.4	4
178	Efficacy of tiotropium–olodaterol fixed-dose combination in COPD. International Journal of COPD, 2016, Volume 11, 3163-3177.	0.9	14
179	The Belgian trial with azithromycin for acute COPD exacerbations requiring hospitalization: an investigator-initiated study protocol for a multicenter, randomized, double-blind, placebo-controlled trial. International Journal of COPD, 2016, 11, 687.	0.9	13
180	Determinants and impact of suboptimal asthma control in Europe: The INTERNATIONAL CROSS-SECTIONAL AND LONGITUDINAL ASSESSMENT ON ASTHMA CONTROL (LIAISON) study. Respiratory Research, 2016, 17, 51.	1.4	110

#	Article	IF	Citations
181	Aggravation of Allergic Airway Inflammation by Cigarette Smoke in Mice Is CD44-Dependent. PLoS ONE, 2016, 11, e0151113.	1.1	13
182	Chronic cigarette smoke exposure induces microbial and inflammatory shifts and mucin changes in the murine gut. Environmental Microbiology, 2016, 18, 1352-1363.	1.8	149
183	Chronic obstructive pulmonary disease and sudden cardiac death: A systematic review. Trends in Cardiovascular Medicine, 2016, 26, 606-613.	2.3	32
184	The heart and pulmonary arterial hypertension in systemic sclerosis. Acta Clinica Belgica, 2016, 71, 1-18.	0.5	13
185	Asthma inflammatory phenotypes show differential microRNA expression in sputum. Journal of Allergy and Clinical Immunology, 2016, 137, 1433-1446.	1.5	168
186	Prevalence and incidence of COPD in smokers and non-smokers: the Rotterdam Study. European Journal of Epidemiology, 2016, 31, 785-792.	2.5	199
187	Vilanterol fluticasone and mortality in comorbid COPD GOLD B. Lancet, The, 2016, 387, 1791-1792.	6.3	1
188	The ever-expanding ERS fellowship programmes: achievements over the past 3 years. European Respiratory Journal, 2016, 48, 595-599.	3.1	1
189	Prostaglandin D 2 receptor antagonism: a novel therapeutic option for eosinophilic asthma?. Lancet Respiratory Medicine,the, 2016, 4, 676-677.	5.2	7
190	AZALEA Trial Highlights Antibiotic Overuse in Acute Asthma Attacks. JAMA Internal Medicine, 2016, 176, 1637.	2.6	7
191	Using a bronchial airway gene expression classifier. Lancet Respiratory Medicine,the, 2016, 4, 694.	5.2	0
192	Lung Function Abnormalities in Smokers with Ischemic Heart Disease. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 568-576.	2.5	53
193	Changes in initial COPD treatment choice over time and factors influencing prescribing decisions in UK primary care: a real-world study. Npj Primary Care Respiratory Medicine, 2016, 26, 16002.	1.1	37
194	The effects of lutein on respiratory health across the life course: AÂsystematic review. Clinical Nutrition ESPEN, 2016, 13, e1-e7.	0.5	28
195	Stabilization of Microcirculation in Patients with Early Systemic Sclerosis with Diffuse Skin Involvement following Rituximab Treatment: An Open-label Study. Journal of Rheumatology, 2016, 43, 995-996.	1.0	39
196	Cardiac effects of current treatments of chronic obstructive pulmonary disease. Lancet Respiratory Medicine,the, 2016, 4, 149-164.	5.2	86
197	Pro- and Anti-Inflammatory Role of ChemR23 Signaling in Pollutant-Induced Inflammatory Lung Responses. Journal of Immunology, 2016, 196, 1882-1890.	0.4	30
198	Six-minute walk test in systemic sclerosis: A systematic review and meta-analysis. International Journal of Cardiology, 2016, 212, 265-273.	0.8	32

#	Article	IF	Citations
199	Treatable traits: toward precision medicine of chronic airway diseases. European Respiratory Journal, 2016, 47, 410-419.	3.1	746
200	The European Respiratory Society evaluates its 2013â€“2018 strategic plan implementation. European Respiratory Journal, 2016, 47, 693-698.	3.1	3
201	Understanding age-related diseases: report of the 2015 Ageing Summit. European Respiratory Journal, 2016, 47, 5-9.	3.1	3
202	Chronic Obstructive Pulmonary Disease and the Risk of Stroke. The Rotterdam Study. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 251-258.	2.5	107
203	Risk of Frailty in Elderly With COPD: A Population-Based Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2016, 71, 689-695.	1.7	130
204	Characterization and Quantification of Innate Lymphoid Cell Subsets in Human Lung. PLoS ONE, 2016, 11, e0145961.	1.1	132
205	Assessment of sensitivity to change of the European Scleroderma Study Group activity index. Clinical and Experimental Rheumatology, 2016, 34 Suppl 100, 148-151.	0.4	1
206	Elucidating COPD pathogenesis by large-scale genetic analyses. Lancet Respiratory Medicine,the, 2015, 3, 737-739.	5.2	6
207	The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK. International Journal of COPD, 2015, 10, 2207.	0.9	85
208	Airway Surface Dehydration Aggravates Cigarette Smoke-Induced Hallmarks of COPD in Mice. PLoS ONE, 2015, 10, e0129897.	1.1	21
209	The Effect of Cigarette Smoke Exposure on the Development of Inflammation in Lungs, Gut and Joints of TNFÎ”ARE Mice. PLoS ONE, 2015, 10, e0141570.	1.1	7
210	Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respiratory Medicine,the, 2015, 3, 355-366.	5.2	937
211	Are the antimicrobial properties of macrolides required for their therapeutic efficacy in chronic neutrophilic airway diseases?. Thorax, 2015, 70, 401-403.	2.7	8
212	Non-coding RNAs in the pathogenesis of COPD. Thorax, 2015, 70, 782-791.	2.7	71
213	Risk of a biased assessment of the evidence when limiting literature searches to the English language: Macrolides in asthma as an illustrative example. Pulmonary Pharmacology and Therapeutics, 2015, 31, 109-110.	1.1	1
214	Chronic obstructive pulmonary disease and sudden cardiac death: the Rotterdam study. European Heart Journal, 2015, 36, 1754-1761.	1.0	91
215	Expression of citrulline and homocitrulline residues in the lungs of non-smokers and smokers: implications for autoimmunity in rheumatoid arthritis. Arthritis Research and Therapy, 2015, 17, 9.	1.6	102
216	Targeted therapy with inhaled corticosteroids in COPD according to blood eosinophil counts. Lancet Respiratory Medicine,the, 2015, 3, 416-417.	5.2	22

#	Article	IF	Citations
217	Gait patterns in COPD: the Rotterdam Study. European Respiratory Journal, 2015, 46, 88-95.	3.1	51
218	Dysregulated fibulin-5 expression and elastogenesis in COPD lungs: pyromaniac or fire fighter?. Thorax, 2015, 70, 1-2.	2.7	406
219	ERS guidelines, statements and technical standards published in theERJin 2014: a year in review. European Respiratory Journal, 2015, 45, 863-866.	3.1	10
220	Molecular mechanisms underlying variations in lung function: a systems genetics analysis. Lancet Respiratory Medicine,the, 2015, 3, 782-795.	5.2	66
221	The Rotterdam study: why fall in COPD?. European Respiratory Journal, 2015, 46, 1530-1531.	3.1	2
222	Role of B Cellâ€“Activating Factor in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 706-718.	2.5	87
223	MicroRNA miR-22 drives TH17 responses in emphysema. Nature Immunology, 2015, 16, 1109-1110.	7.0	3
224	Real-world research and its importance in respiratory medicine. Breathe, 2015, 11, 26-38.	0.6	66
225	Chronic obstructive pulmonary disease and cerebrovascular disease: A comprehensive review. Respiratory Medicine, 2015, 109, 1371-1380.	1.3	94
226	Transforming Growth Factor-Î² Superfamily in Obstructive Lung Diseases. More Suspects Than TGF-Î² Alone. American Journal of Respiratory Cell and Molecular Biology, 2015, 52, 653-662.	1.4	40
227	Non-coding RNAs and respiratory disease. Thorax, 2015, 70, 388-390.	2.7	22
228	Prevalence of Pulmonary Hypertension in the General Population: The Rotterdam Study. PLoS ONE, 2015, 10, e0130072.	1.1	57
229	Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns. International Journal of COPD, 2014, 9, 889.	0.9	210
230	Large-Scale Genome-Wide Association Studies and Meta-Analyses of Longitudinal Change in Adult Lung Function. PLoS ONE, 2014, 9, e100776.	1.1	52
231	Targeting Immune Pathways for Therapy in Asthma and Chronic Obstructive Pulmonary Disease. Annals of the American Thoracic Society, 2014, 11, S322-S328.	1.5	85
232	Early origins of chronic obstructive lung diseases across the life course. European Journal of Epidemiology, 2014, 29, 871-885.	2.5	102
233	Is there a role for macrolides in severe asthma?. Current Opinion in Pulmonary Medicine, 2014, 20, 95-102.	1.2	42
234	Role of activin-A in cigarette smoke-induced inflammation and COPD. European Respiratory Journal, 2014, 43, 1028-1041.	3.1	36

#	Article	IF	Citations
235	Trustworthy guidelines on severe asthma thanks to the ERS and ATS. European Respiratory Journal, 2014, 43, 315-318.	3.1	10
236	Investigation of 5-HT4 receptors in bronchial hyperresponsiveness in cigarette smoke-exposed mice. Pulmonary Pharmacology and Therapeutics, 2014, 28, 60-67.	1.1	9
237	Mechanistic links between COPD and lung cancer: a role of microRNA let-7?. Nature Reviews Cancer, 2014, 14, 70-70.	12.8	22
238	Role of the nitric oxideâ€“soluble guanylyl cyclase pathway in obstructive airway diseases. Pulmonary Pharmacology and Therapeutics, 2014, 29, 1-6.	1.1	39
239	Genome-wide association analysis identifies six new loci associated with forced vital capacity. Nature Genetics, 2014, 46, 669-677.	9.4	131
240	Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma. New England Journal of Medicine, 2014, 371, 1198-1207.	13.9	1,807
241	Common genes underlying asthma and COPD? Genome-wide analysis on the Dutch hypothesis. European Respiratory Journal, 2014, 44, 860-872.	3.1	49
242	Why doesn't reducing exacerbations decrease COPD mortality?. Lancet Respiratory Medicine,the, 2014, 2, 681-683.	5.2	8
243	Self-Medication in Persistent Rhinitis: Overuse of Decongestants in Half of the Patients. Journal of Allergy and Clinical Immunology: in Practice, 2014, 2, 313-319.	2.0	32
244	Should we pursue pulmonary vasodilation in patients with COPD?. Lancet Respiratory Medicine,the, 2014, 2, 252-254.	5.2	0
245	Inflammasomes in Respiratory Disease. Chest, 2014, 145, 1121-1133.	0.4	72
246	Susceptibility to Chronic Mucus Hypersecretion, a Genome Wide Association Study. PLoS ONE, 2014, 9, e91621.	1.1	25
247	Statins, systemic inflammation and risk of death in COPD: The Rotterdam study. Pulmonary Pharmacology and Therapeutics, 2013, 26, 212-217.	1.1	102
248	Eosinophils in the Spotlight: Eosinophilic airway inflammation in nonallergic asthma. Nature Medicine, 2013, 19, 977-979.	15.2	264
249	Role of CXCL13 in Cigarette Smokeâ€“induced Lymphoid Follicle Formation and Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 343-355.	2.5	83
250	Of flies, mice and men: a systematic approach to understanding the early life origins of chronic lung disease. Thorax, 2013, 68, 380-384.	2.7	34
251	Chronic Obstructive Pulmonary Disease and Lipid Core Carotid Artery Plaques in the Elderly. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 58-64.	2.5	83
252	Integrating real-life studies in the global therapeutic research framework. Lancet Respiratory Medicine,the, 2013, 1, e29-e30.	5.2	102

#	Article	IF	Citations
253	Leptin as regulator of pulmonary immune responses: Involvement in respiratory diseases. Pulmonary Pharmacology and Therapeutics, 2013, 26, 464-472.	1.1	60
254	Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax, 2013, 68, 322-329.	2.7	421
255	The Role of Soluble Guanylyl Cyclase in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 789-799.	2.5	30
256	Chronic Obstructive Pulmonary Disease and Cerebral Microbleeds. The Rotterdam Study. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 783-788.	2.5	63
257	Genome-Wide Association Studies Identify CHRNA5/3 and HTR4 in the Development of Airflow Obstruction. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 622-632.	2.5	164
258	Smoke decreases reversible oxidations S-glutathionylation and S-nitrosylation in mice. Free Radical Research, 2012, 46, 164-173.	1.5	12
259	Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2012, 22, 92-100.	2.5	148
260	Real-life effectiveness of extrafine beclometasone dipropionate/formoterol in adults with persistent asthma according to smoking status. Respiratory Medicine, 2012, 106, 811-819.	1.3	43
261	Targeting Interleukin-4 in Asthma: Lost in Translation?. American Journal of Respiratory Cell and Molecular Biology, 2012, 47, 261-270.	1.4	111
262	Altered Cigarette Smoke-Induced Lung Inflammation Due to Ablation of Grx1. PLoS ONE, 2012, 7, e38984.	1.1	20
263	New insights into the immunology of chronic obstructive pulmonary disease. Lancet, The, 2011, 378, 1015-1026.	6.3	609
264	Exacerbation of cigarette smoke-induced pulmonary inflammation by Staphylococcus aureus Enterotoxin B in mice. Respiratory Research, 2011, 12, 69.	1.4	29
265	MicroRNA Expression in Induced Sputum of Smokers and Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 898-906.	2.5	209
266	Activation of the WNT/Î²-Catenin Pathway Attenuates Experimental Emphysema. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 723-733.	2.5	162
267	Mendelian Randomization Study of Interleukin-6 in Chronic Obstructive Pulmonary Disease. Respiration, 2011, 82, 530-538.	1.2	24
268	Neomacrolides in the treatment of patients with severe asthma and/or bronchiectasis: a retrospective observational study. Therapeutic Advances in Respiratory Disease, 2011, 5, 377-386.	1.0	18
269	The Role of ChemR23 in the Induction and Resolution of Cigarette Smoke-Induced Inflammation. Journal of Immunology, 2011, 186, 5457-5467.	0.4	56
270	Genome-wide association and large-scale follow up identifies 16 new loci influencing lung function. Nature Genetics, 2011, 43, 1082-1090.	9.4	367

#	Article	IF	Citations
271	A4 Dendritic cells. , 2011, , 47-57.		0
272	Selective accumulation of langerhans-type dendritic cells in small airways of patients with COPD. Respiratory Research, 2010, 11, 35.	1.4	77
273	Different regulation of cigarette smoke induced inflammation in upper versus lower airways. Respiratory Research, 2010, 11, 100.	1.4	31
274	Meta-analyses of genome-wide association studies identify multiple loci associated with pulmonary function. Nature Genetics, 2010, 42, 45-52.	9.4	549
275	Leptin Modulates Innate and Adaptive Immune Cell Recruitment after Cigarette Smoke Exposure in Mice. Journal of Immunology, 2010, 184, 7169-7177.	0.4	46
276	Enhanced Deposition of Low-Molecular-Weight Hyaluronan in Lungs of Cigarette Smokeâ€“Exposed Mice. American Journal of Respiratory Cell and Molecular Biology, 2010, 42, 753-761.	1.4	51
277	The role of interleukin-6 in pulmonary and systemic manifestations in a murine model of chronic obstructive pulmonary disease. Experimental Lung Research, 2010, 36, 469-483.	0.5	13
278	Cigarette smoke induces PTX3 expression in pulmonary veins of mice in an IL-1 dependent manner. Respiratory Research, 2010, 11, 134.	1.4	21
279	The Role of Dendritic Cells in the Pathogenesis of COPD: Liaison Officers in the Front Line. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2009, 6, 284-290.	0.7	30
280	CCR7 Modulates Pulmonary and Lymph Node Inflammatory Responses in Cigarette Smoke-Exposed Mice. Journal of Immunology, 2009, 183, 8186-8194.	0.4	28
281	Matrix Metalloproteinase 12, Asthma, and COPD. New England Journal of Medicine, 2009, 361, 2664-2665.	13.9	18
282	Lymphoid follicles in (very) severe COPD: beneficial or harmful?. European Respiratory Journal, 2009, 34, 219-230.	3.1	111
283	Concomitant Inhalation of Cigarette Smoke and Aerosolized Protein Activates Airway Dendritic Cells and Induces Allergic Airway Inflammation in a TLR-Independent Way. Journal of Immunology, 2009, 183, 2758-2766.	0.4	36
284	C-Reactive Protein Levels, Haplotypes, and the Risk of Incident Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 375-382.	2.5	51
285	Role of the tachykinin NK1 receptor in a murine model of cigarette smoke-induced pulmonary inflammation. Respiratory Research, 2009, 10, 37.	1.4	23
286	Extrapulmonary Manifestations of Chronic Obstructive Pulmonary Disease in a Mouse Model of Chronic Cigarette Smoke Exposure. American Journal of Respiratory Cell and Molecular Biology, 2009, 40, 710-716.	1.4	79
287	Dendritic Cells in Asthma and COPD. , 2009, , 121-132.		0
288	Prevalence, Incidence, and Lifetime Risk for the Development of COPD in the Elderly. Chest, 2009, 135, 368-377.	0.4	130

#	Article	IF	Citations
289	TNFÎ± receptor genotype influences smoking-induced muscle-fibre-type shift and atrophy in mice. Acta Neuropathologica, 2008, 115, 675-681.	3.9	24
290	Comment on â€œCigarette Smoke-Induced Pulmonary Inflammation Is TLR4/MyD88 and IL-1R1/MyD88 Signaling Dependentâ€• Journal of Immunology, 2008, 180, 5761.1-5761.	0.4	2
291	Dendritic Cells in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 1180-1186.	2.5	83
292	Chemokine Receptor CCR2 but Not CCR5 or CCR6 Mediates the Increase in Pulmonary Dendritic Cells during Allergic Airway Inflammation. Journal of Immunology, 2007, 178, 5305-5311.	0.4	115
293	Accumulation of Dendritic Cells and Increased CCL20 Levels in the Airways of Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2007, 175, 998-1005.	2.5	213
294	CC-Chemokine Receptors in Chronic Obstructive Pulmonary Disease. Inflammation and Allergy: Drug Targets, 2007, 6, 75-79.	1.8	37
295	Dendritic Cell Maturity and Obstructive Airway Disease. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 833-834.	2.5	3
296	Matrix metalloproteinases -8, -9 and -12 in smokers and patients with stage 0 COPD. International Journal of COPD, 2007, 2, 369-79.	0.9	45
297	Cigarette smoke exposure facilitates allergic sensitization in mice. Respiratory Research, 2006, 7, 49.	1.4	68
298	Role of apoptosis in the pathogenesis of COPD and pulmonary emphysema. Respiratory Research, 2006, 7, 53.	1.4	411
299	Different Roles for Human Lung Dendritic Cell Subsets in Pulmonary Immune Defense Mechanisms. American Journal of Respiratory Cell and Molecular Biology, 2006, 35, 387-393.	1.4	115
300	Murine TLR4 Is Implicated in Cigarette Smoke-Induced Pulmonary Inflammation. International Archives of Allergy and Immunology, 2006, 141, 354-368.	0.9	87
301	Cigarette Smoke-Induced Pulmonary Inflammation and Emphysema Are Attenuated in CCR6-Deficient Mice. Journal of Immunology, 2006, 177, 4350-4359.	0.4	221
302	Identification and Characterization of Human Pulmonary Dendritic Cells. American Journal of Respiratory Cell and Molecular Biology, 2005, 32, 177-184.	1.4	217
303	Matrix Metalloproteinase-12 and Cathepsin D Expression in Pulmonary Macrophages and Dendritic Cells of Cigarette Smoke-Exposed Mice. International Archives of Allergy and Immunology, 2005, 138, 169-179.	0.9	88
304	Matrix metalloproteinases in asthma and COPD. Current Opinion in Pharmacology, 2005, 5, 257-263.	1.7	146
305	Cigarette smoke-induced pulmonary emphysema in scid-mice. Is the acquired immune system required?. Respiratory Research, 2005, 6, 147.	1.4	94